

Supporting Information

Supplementary methods and results

This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix to: Pandeya N, Olsen CM, Shalit MM, et al. The diagnosis and initial management of melanoma in Australia: findings from the prospective, population-based QSkin study. *Med J Aust* 2023; doi: 10.5694/mja2.51919.

	Procedure	Item Numbers	Description
SURGICAL	Melanoma	31300	nose, eyelid, lip, ear, digit or genitalia; ≤ 10 mm in diameter
EXCISION		31305	nose, eyelid, lip, ear, digit or genitalia; > 10 mm in diameter
		31310	face, neck or lower leg; ≤ 10 mm in diameter
		31315	face, neck or lower leg; $> 10 \text{ mm and} \le 20 \text{ mm in diameter}$
		31320	face, neck or lower leg; > 20 mm in diameter
		31325	other areas of the body; $\leq 10 \text{ mm}$ in diameter
		31330	other areas of the body; $> 10 \text{ mm and} \le 20 \text{ mm in diameter}$
		31335	other areas of the body; > 20 mm in diameter
	Benign lesions to	31205	single lesion; ≤ 10 mm in diameter
	exclude melanoma	31210	single lesion; $> 10 \text{ mm}$ and $\le 20 \text{ mm}$ in diameter
		31215	single lesion; > 20 mm in diameter
		31220	4-10 lesions; ≤ 10 mm in diameter
		31225	>10 lesions; ≤ 10 mm in diameter
		31230	nose, eyelid, lip, ear, digit or genitalia
		31235	face, neck or lower leg; ≤ 10 mm in diameter
		31240	face, neck or lower leg; ≤ 10 mm in diameter
	BCC/SCC, first	31255	nose, eyelid, lip, ear, digit or genitalia; ≤ 10 mm in diameter
	surgical excision	31260	nose, eyelid, lip, ear, digit or genitalia; > 10 mm in diameter
	0	31265	face, neck or lower leg; ≤ 10 mm in diameter
		31270	face, neck or lower leg; ≥ 10 mm and ≤ 20 mm in diameter
		31275	face, neck or lower leg; > 20 mm in diameter face, neck or lower leg; > 20 mm in diameter
		31280	other areas of the body; ≤ 10 mm in diameter
		31285	other areas of the body; ≥ 10 mm and ≤ 20 mm in diameter other areas of the body; > 10 mm and ≤ 20 mm in diameter
		31290	other areas of the body; > 20 mm in diameter
	Residual and	31256, 31261,	other areas of the body, > 20 min in diameter
	Recurrent	31266, 31271,	
	BCC/SCC,	31276, 31281,	
	previously treated		
		31286, 31291,	
	surgically	31257, 31262,	
		31267, 31272,	
		31277, 31282,	
		31287, 31292,	
		31258, 31263,	
		31268, 31273,	
		31278, 31283,	
		31288, 31293	
	Residual and	31295	
	Recurrent		
	BCC/SCC,		
	previously treated		
	non- surgically		
	MI	21000	
	Moh surgery	31000	
		31001	
		31002	
BIOPSY	Biopsy	30071	
OTHER	Benign lesion	30195	
TREATMENT (cryotherapy or	Premalignant lesion	30192	
serial curettage)	Malianan(1)	20106 20107	
	Malignant lesion	30196, 30197,	
		30202, 30203,	
		30205 pus Cell Carcinoma	

Table 1. MBS item numbers for the diagnosis and treatment of skin cancers and benign skin lesions, 2011-2015


BCC: Basal Cell Carcinoma; SCC: Squamous Cell Carcinoma.


Table 2. MBS item numbers for the diagnosis and treatment of skin cancers and benign skin lesions,
2016-2019

	Procedure	Item Numbers	Description
SURGICAL	Melanoma	31371	nose, eyelid, lip, ear, digit or genitalia; ≥6 mm in diameter
EXCISION		31372	face, neck, scalp, nipple-areola complex, distal lower limb
			(distal to, and including, the knee) or distal upper limb (distal to,
			and including, the ulnar styloid); <14 mm in diameter
		31373	face, neck, scalp, nipple-areola complex, distal lower limb
			(distal to, and including, the knee) or distal upper limb (distal
			to, and including, the ulnar styloid); ≥ 14 mm in diameter
		31374	other areas of the body; <15mm
		31375	other areas of the body; 15-30 mm
		31376	other areas of the body; >30 mm in diameter
	Benign lesions to	31357	nose, eyelid, lip, ear, digit or genitalia; <6 mm in diameter
	exclude melanoma	31360	nose, eyelid, lip, ear, digit or genitalia; ≥6 mm in diameter
		31362	face, neck, scalp, nipple-areola complex, distal lower limb
			(distal to, and including, the knee) or distal upper limb (distal to,
			and including, the ulnar styloid); <14 mm in diameter
		31364	face, neck, scalp, nipple-areola complex, distal lower limb
			(distal to, and including, the knee) or distal upper limb (distal to,
			and including, the ulnar styloid); <14 mm in diameter
		31366	other areas of the body; <15mm
		31368	other areas of the body; 15-30 mm
		31370	other areas of the body; >30 mm in diameter
	BCC/SCC, first	31356	nose, eyelid, lip, ear, digit or genitalia; <6 mm in diameter
	surgical excision	31358	nose, eyelid, lip, ear, digit or genitalia; ≥6 mm in diameter
		31359	nose, eyelid, lip, ear, digit or genitalia; excision area at least one
			third of surface area of the site
		31361	face, neck, scalp, nipple-areola complex, distal lower limb
			(distal to, and including, the knee) or distal upper limb (distal to,
			and including, the ulnar styloid); <14 mm in diameter
		31363	face, neck, scalp, nipple-areola complex, distal lower limb
			(distal to, and including, the knee) or distal upper limb (distal to,
			and including, the ulnar styloid); <14 mm in diameter
		31365	other areas of the body; <15mm
		31367	other areas of the body; 15-30 mm
		31369	other areas of the body; >30 mm in diameter
	Residual and	31256, 31261,	
	recurrent	31266, 31271,	
	BCC/SCC,	31276, 31281,	
	previously treated	31286, 31291,	
	surgically	31257, 31262,	
		31267, 31272,	
		31277, 31282,	
		31287, 31292,	
		31258, 31263,	
		31268, 31273,	
		31278, 31283,	
		31288, 31293	
	Residual and	31295	
	Recurrent		
	BCC/SCC,		
	previously treated		
	non- surgically		
	Moh surgery	31000	
		31001	

	Procedure	Item Numbers	Description
		31002	
BIOPSY	Biopsy	30071	
OTHER TREATMENT	Benign lesion	30195	
(cryotherapy or serial curettage)	Premalignant lesion	30192	
	Malignant lesion	30196, 30197, 30202, 30203, 30205	

BCC: Basal Cell Carcinoma; SCC: Squamous Cell Carcinoma.





		Primary care			General			
Variable	Total	practitioner	Dermatologist	Plastic surgeon	surgeon	Other specialist	Missing data	P*
Total number	1683	1296	248	83	43	10		
Age at baseline								0.96
40-49	290 (17.2%)	219 (16.9%)	47 (19%)	15 (18%)	8 (19%)	1 (10%)	-	
50-59	617 (36.7%)	478 (36.9%)	92 (37%)	31 (37%)	13 (30%)	3 (30%)	-	
60+	776 (46.1%)	599 (46.2%)	109 (44%)	37 (45%)	22 (51%)	6 (60%)	3	
Sex								0.71
Women	720 (42.8%)	547 (42.2%)	113 (45.6)	33 (40%)	21 (49%)	5 (50%)	1	
Men	963 (57.2%)	749 (57.8%)	135 (54.4)	50 (60%)	22 (51%)	5 (50%)	2	
Education								<0.001
No school certificate	112 (7.2%)	99 (8.3%)	6 (3%)	5 (7%)	2 (5%)	0		
School certificate	543 (35.1%)	431 (36.2%)	67 (29%)	28 (37%)	14 (35%)	3 (33%)		
Trade/diploma	474 (30.6%)	387 (32.5%)	54 (23%)	11 (14%)	16 (40%)	5 (56%)	1	
University degree	419 (27.1%)	272 (22.9%)	105 (45%)	32 (42%)	8 (20%)	1 (11%)	1	
Missing	135	107	16	7	3	1		
Private health insurance								<0.001
No	444 (26.4%)	389 (30.1%)	26 (10%)	11 (13%)	14 (33%)	3 (30%)	1	
Yes	1236 (73.6%)	904 (69.9%)	222 (89.5%)	72 (87%)	29 (67%)	7 (70%)	2	
Missing	3	3	-	-	-	-		
Region of residence ¹								<0.001
Urban	1114 (66.2%)	815 (62.9%)	216 (87.1%)	59 (71%)	16 (38%)	7 (70%)	1	
Rural	556 (33.1%)	473 (36.5%)	28 (11%)	24 (29%)	26 (60%)	3 (30%)	2	
Remote	12 (0.7%)	7 (0.5%)	4 (2%)	0	1 (2%)	0	-	
Missing	1	1	-	-	-	-		
Skin check in 3 years prior to								0.001
baseline								0.001
None	243 (14.6%)	204 (16.0%)	18 (7.3%)	11 (13%)	9 (21%)	1 (10%)		
1	419 (25.2%)	338 (26.5%)	49 (20%)	21 (26%)	9 (21%)	1 (10%)	1	
2 or more	1000 (60.2%)	734 (57.5%)	181 (73.0%)	50 (61%)	25 (58%)	8 (80%)	2	

Table 3. Characteristics of all QSkin participants with an incident melanoma during follow-up, and according to treating practitioner for first excision.

		Primary care			General			
Variable	Total	practitioner	Dermatologist	Plastic surgeon	surgeon	Other specialist	Missing data	P*
Missing	21	20	-	1	-			
Clinical risk score								0.001
Q1	115 (6.8%)	96 (7.4%)	14 (5.6%)	2 (2%)	3 (7%)	0		
Q2	264 (15.7%)	213 (16.4%)	29 (12%)	12 (14%)	7 (16%)	3 (30%)		
Q3	464 (27.6%)	378 (29.2%)	49 (20%)	20 (24%)	15 (35%)	0	2	
Q4	840 (49.9%)	609 (47.0%)	156 (63%)	49 (59%)	18 (42%)	7 (70%)	1	
Family history of melanoma								0.41
No	960 (65.5%)	735 (65.2%)	139 (62.6%)	54 (75%)	24 (69%)	5 (71%)	3	
Yes	506 (34.5%)	392 (34.8%)	83 (37%)	18 (25%)	11 (31%)	2 (29%)	-	
Missing	217	171	26	11	8	3		
Past excisions for skin cancer								0.002
None	658 (39.5%)	540 (42.1%)	70 (28%)	26 (32%)	16 (37%)	4 (40%)	2	
1	263 (15.8%)	206 (16.0%)	38 (15%)	12 (15%)	7 (16%)	0	-	
2+	747 (44.8%)	538 (41.9%)	138 (56%)	44 (54%)	20 (46%)	6 (60%)	1	
Missing	15	13	2	1	-			
Past skin lesions destroyed								0.010
None	421 (25.1%)	344 (26.7%)	44 (18%)	17 (20%)	13 (30%)	2 (20%)	1	
1-5	436 (26.0%)	345 (26.8%)	59 (24%)	16 (19%)	13 (30%)	3 (30%)	-	
6-20	445 (26.6%)	341 (26.5%)	68 (27%)	25 (30%)	8 (19%)	2 (20%)	1	
21+	373 (22.3%)	258 (20.0%)	77 (31%)	25 (30%)	9 (21%)	3 (30%)	1	
Missing	8	8	-	-	-			

* χ^2 test.

(1) Australian Bureau of Statistics. 1270.0.55.005. Australian Statistical Geography Standard (ASGS): Volume 5. Remoteness Structure, July 2011. 31 Jan 2013. https://www.abs.gov.au/ausstats/abs@.nsf/Lookup/1270.0.55.005main+features1july+2011 (viewed Dec 2022).

				Second wide		
Variables	Shave biopsy	Punch biopsy	First excision	excision	Other	P*
Total number	549	178	854	44	58	
Age at baseline						0.93
40-49	99 (18%)	27 (15%)	148 (17%)	9 (20%)	7 (12%)	
50-59	193 (35.2%)	70 (39%)	314 (37%)	17 (39%)	23 (40%)	
60+	257 (46.8%)	81 (46%)	392 (46%)	18 (41%)	28 (48%)	
Sex						0.012
Women	238 (43.4%)	90 (51%)	338 (40%)	25 (57%)	29 (50%)	
Men	311 (56.6%)	88 (49%)	516 (60%)	19 (43%)	29 (50%)	
Education						0.45
No school certificate	35 (6.9%)	12 (7.3%)	60 (7.7%)	2 (5%)	3 (6%)	
School certificate	161 (31.9%)	67 (41%)	286 (36.5%)	12 (29%)	17 (32%)	
Trade/diploma	154 (30.5%)	44 (27%)	244 (31.2%)	16 (38%)	16 (30%)	
University degree	155 (30.7%)	41 (25%)	193 (24.6%)	12 (29%)	18 (33%)	
Missing	44	14	71	2	4	
Private health insurance						0.18
No	136 (24.8%)	47 (26%)	242 (28.4%)	10 (23%)	9 (16%)	
Yes	412 (75.2%)	131 (73.6%)	610 (71.6%)	34 (77%)	49 (84%)	
Missing	1	-	2	-	-	
Region of residence ¹						< 0.001
Urban	428 (78.0%)	118 (66.7%)	496 (58.1%)	30 (68%)	42 (72%)	
Rural	115 (20.9%)	59 (33%)	352 (41.2%)	14 (32%)	16 (28%)	
Remote	6 (1%)	0	6 (0.7%)	0	0	
Missing	-	1	-	-	-	
Skin check in 3 years prior to l	oaseline					0.037
None	70 (13%)	27 (15%)	134 (15.8%)	6 (14%)	6 (11%)	
1	112 (20.7%)	55 (31%)	227 (26.8%)	12 (28%)	13 (23%)	
2 or more	358 (66.3%)	95 (54%)	485 (57.3%)	25 (58%)	37 (66%)	

Table 4. Treatment modality for the first tissue sample of the first incident melanoma according to patient characteristics

				Second wide		
Variables	Shave biopsy	Punch biopsy	First excision	excision	Other	Р*
Missing	9	1	8	1	2	
Melanoma clinical risk predictio	on score					0.97
Q1	35 (6.4%)	13 (7.3%)	60 (7.0%)	4 (9%)	3 (5%)	
Q2	87 (16%)	31 (17%)	126 (14.8%)	8 (18%)	12 (21%)	
Q3	160 (29.1%)	50 (28%)	229 (26.8%)	11 (25%)	14 (24%)	
Q4	267 (48.6%)	84 (47%)	439 (51.4%)	21 (48%)	29 (50%)	
Family history of melanoma						0.41
No	302 (63.7%)	103 (64%)	495 (66%)	29 (78%)	31 (65%)	
Yes	172 (36.3%)	59 (36%)	250 (34%)	8 (22%)	17 (35%)	
Missing	75	16	109	7	10	
Past excisions for skin cancer						0.20
None	202 (37.1%)	81 (46%)	340 (40%)	19 (43%)	16 (28%)	
1	85 (16%)	28 (16%)	136 (16%)	4 (9%)	10 (17%)	
2+	258 (47.3%)	66 (38%)	370 (44%)	21 (48%)	32 (55%)	
Missing	4	3	8	-	-	
Past skin lesions destroyed						0.90
None	126 (23.1%)	47 (27%)	228 (26.8%)	11 (25%)	9 (16%)	
1-5	142 (26.1%)	48 (27%)	217 (25.5%)	11 (25%)	18 (32%)	
6-20	153 (28.1%)	44 (25%)	222 (26.1%)	11 (25%)	15 (26%)	
21+	124 (22.8%)	38 (22%)	185 (21.7%)	11 (25%)	15 (26%)	
Missing	4	1	2	-	1	

* χ² test.

(1) Australian Bureau of Statistics. 1270.0.55.005. Australian Statistical Geography Standard (ASGS): Volume 5. Remoteness Structure, July 2011. 31 Jan 2013. https://www.abs.gov.au/ausstats/abs@.nsf/Lookup/1270.0.55.005main+features1july+2011 (viewed Dec 2022).